Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve Inc. is a Canadian healthcare technology company. The Company and its subsidiaries, Medivolve Pharmacy Inc. (doing business as Marbella Pharmacy) and Kedy Ying Jao D.O., a Medical Corporation, operate a distributed network of two retail patient-care locations in California, United States. It has two business units: Medivolve Pharmacy Division (MPD) and Medivolve Clinic Services Division (MCSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine and psychiatry to patients in Southern California. MCSD provides licensed healthcare through a clinic in Brea, California, United States. MCSD is focused on developing a telehealth platform, which connects patients with physicians, and facilitates and manages the provision of virtual consultation, diagnosis, and treatment services in partnership with qualified health practitioners.


OTCPK:MEDVF - Post by User

Post by Sarb99on Jan 14, 2021 8:24pm
339 Views
Post# 32303243

Medivolve can capitalize on 50 billion new funds for testing

Medivolve can capitalize on 50 billion new funds for testing

Medivolve is in the best place to take advantage of this $50 billion investment into the covid-19 testing by Joe Biden GOVT. Medivolve does not need to wait for any approval. They already have 46 testing sites up and running and 10 more ready to go. The second phase already underway to install another 63 testing sites. Medivolve already has signed a contract with 743 shopping malls and gas stations to add testing sites. 

 

WillScot says they have a lot of supply to install these mobile testing sites. Medivolve should quickly complete previously announced $5 million private placement and get to work. Fill up most of those 743 locations by the end of February or 15-20 new sites installing every week. 

 

Most of the other Covid19 plays are not even approved in the USA to offer tests. Also, Biden said, he wants to create more spaces for vaccination. Again Medivolve, with all these testing sites, can take advantage and get a vaccination contract.  

 

https://www.washingtonpost.com/us-policy/2021/01/14/biden-stimulus-covid-relief/

 

The proposal will aim to make good on Biden’s plan for a universal vaccination program, devoting $20 billion to that goal, as well as $50 billion for a “massive expansion” of testing and $130 billion to help schools reopen safely. Among the many goals laid out in the proposal, Biden hopes to deliver 100 million vaccine shots in 100 days and reopen a majority of K-12 public schools in that time frame.

<< Previous
Bullboard Posts
Next >>